- Home
- RQI vs MESO Comparison
RQI vs MESO Comparison
Compare RQI & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RQI | MESO |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RQI | MESO |
|---|---|---|
| Price | $11.62 | $18.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | ★ 432.6K | 227.7K |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | ★ 8.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $17,198,000.00 |
| Revenue This Year | N/A | $576.59 |
| Revenue Next Year | N/A | $41.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 191.39 |
| 52 Week Low | $9.17 | $9.61 |
| 52 Week High | $12.64 | $21.88 |
Technical Indicators
Market Signals| Indicator | RQI | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 51.11 | 51.92 |
| Support Level | $11.37 | $17.90 |
| Resistance Level | $11.60 | $19.60 |
| Average True Range (ATR) | 0.11 | 0.54 |
| MACD | 0.02 | -0.17 |
| Stochastic Oscillator | 91.91 | 33.04 |
Price Performance
Historical ComparisonAbout RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.